Skip to main content
. 2022 May 5;9(5):200. doi: 10.3390/bioengineering9050200

Figure 4.

Figure 4

PPTT + chemotherapy using AuNRs. (A) Dox-conjugated pH-responsive AuNRs for PPTT + chemotherapy. Left: Schematic of the synthesis of the AuNR conjugates and its application for combined PPTT and chemotherapy. Right: Average HepG2 tumor volume of the mice at different days after different treatments. Cited from Ref. [104]. * indicates significant difference at p < 0.05 and ** indicates significant difference at p < 0.01. Copyright@2018, Chen, J.; Li, X.; Zhao, X.; Wu, Q.; Zhu, H.; Mao, Z.; Gao, C. (B) Dox-conjugated light-sensitive AuNRs for PPTT + chemotherapy. Left: Schematic of the preparation of P-GNRs-Dox and light sensitive drug release mechanism. Right: Relative C26 tumor volume of the mice at different days after different treatments. * indicates significant difference at p < 0.05. Cited from Ref. [108]. Copyright @2015, Liao, J.; Li, W.; Peng, J.; Enzu, Q.; Li, H.; Wei, Y.; Zhang, X.; Qian, Z. (C) Paclitaxel (PTX)/CUR/AuNRs@c-RGD complex for PPTT + chemotherapy. Left: Schematic of the preparation and application of the complex for PPTT + chemotherapy. PTX is released by hydrophobic interaction and CUR is released by enzymatic hydrolysis. Right: Average A549 tumor volume of the mice at different days after different treatments. Cited from Ref. [113]. * indicates significant difference at p < 0.05. * p < 0.05 vs. PTX/CUR/AuNRs@CRGD and # p < 0.05 vs. PEG/AuNRs@cRGD+laser. Copyright@2019, Zhu, F.; Tan, G.; Zhong, Y.; Jiang, Y.; Cai, L.; Yu, Z.; Liu, S.; Ren, F.